Drug Resistance Mutations (DRMs) for Long-Acting Injectable Cabotegravir and Rilpivirine (CAB/RPV LAI) in the HIV-1 Subtype A6 Epidemic in Poland. [PDF]
MicroorganismsZałęski A +7 more
europepmc +1 more source
Prevalence of drug resistance mutations in low-level viremia patients under antiretroviral therapy in Southwestern China: a cross-sectional study. [PDF]
J Antimicrob ChemotherShu Y +7 more
europepmc +1 more source
Risk of viral failure after simplification therapy without using integrase inhibitors compared with maintenance of triple antiretroviral therapy: A systematic review and meta-analysis. [PDF]
Braz J Infect DisHelfer MS, Sprinz E.
europepmc +1 more source
Structural Virology: The Key Determinants in Development of Antiviral Therapeutics. [PDF]
VirusesHanda T +6 more
europepmc +1 more source
The miRNomics of antiretroviral therapy-induced obesity. [PDF]
Funct Integr GenomicsMajumdar N +7 more
europepmc +1 more source
Emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second-generation InSTIs in two- and three-drug regimens: the Virostar-1 study. [PDF]
J Antimicrob ChemotherMarcelin AG +7 more
europepmc +1 more source
DEFINE: A Prospective, Randomized, Phase 4 Trial to Assess a Protease Inhibitor-Based Regimen Switch Strategy to Manage Integrase Inhibitor-Related Weight Gain. [PDF]
Clin Infect DisAnderson D +8 more
europepmc +1 more source
Non-Communicable Diseases in Patients with Human Immunodeficiency Virus and Their Risk Factors. [PDF]
Infect ChemotherDaniella D, Gayatri AAAY, Somia IKA.
europepmc +1 more source
HIV-1 protease inhibitors and mechanisms of HIV-1's resistance. [PDF]
Glob Health MedDas D.
europepmc +1 more source